1. Home
  2. COGT vs AXTA Comparison

COGT vs AXTA Comparison

Compare COGT & AXTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$35.72

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Logo Axalta Coating Systems Ltd.

AXTA

Axalta Coating Systems Ltd.

HOLD

Current Price

$32.35

Market Cap

6.8B

ML Signal

HOLD

Company Overview

Basic Information
Metric
COGT
AXTA
Founded
2014
1910
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Paints/Coatings
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
6.8B
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
COGT
AXTA
Price
$35.72
$32.35
Analyst Decision
Buy
Buy
Analyst Count
13
13
Target Price
$30.00
$36.77
AVG Volume (30 Days)
2.5M
3.7M
Earning Date
11-03-2025
02-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
40.67
EPS
N/A
2.09
Revenue
N/A
$5,166,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.12
P/E Ratio
N/A
$15.68
Revenue Growth
N/A
N/A
52 Week Low
$3.72
$26.28
52 Week High
$43.73
$38.37

Technical Indicators

Market Signals
Indicator
COGT
AXTA
Relative Strength Index (RSI) 45.35 65.66
Support Level $37.23 $31.98
Resistance Level $40.59 $33.11
Average True Range (ATR) 1.81 0.61
MACD -1.02 0.09
Stochastic Oscillator 19.06 79.06

Price Performance

Historical Comparison
COGT
AXTA

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About AXTA Axalta Coating Systems Ltd.

Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific, and Latin America.

Share on Social Networks: